Skip to content

Comparison of the effects of medroxyprogestron and megestrol on vasomotor symptom in menopause women

Comparison of the effects of medroxyprogestron 10 mg and megestrol 40 mg on vasomotor symptom in menopause women

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210412050945N1
Enrollment
80
Registered
2021-05-02
Start date
2021-05-10
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopausal hot flashes. Menopausal and other perimenopausal disorders

Interventions

Intervention 1: Intervention group: Magestrol tablets 40 mg daily for 1 month. Intervention 2: Intervention group: Medroxyprogesterone 10 mg daily for one month.

Sponsors

Karaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Iranian women 40-60 years old Married With a history of childbirth; She had the last period 12 month later and serum FSH level is more than 40 million units per ml; Lack of known physical or mental illness; Experience at least 3 hot flashes during the day No addiction or smoking, hookah or alcohol Body mass index less than or equal to 29 Minimum literacy Women with and had at least one of the symptoms of menopausal vasomotor Natural menopause and menopause due to ovarian removal No known mental illness

Exclusion criteria

Exclusion criteria: Regular exercise program Vegetarian diet Consume soy and its products more than once a week Current use of drugs that affect hot flashes. Symptoms of drug allergy Failure to record the number of hot flashes in the relevant checklists Taking any medicine during research The presence of severe stress during treatment

Design outcomes

Primary

MeasureTime frame
Intensity of hot flashes. Timepoint: Before and one month after the intervention. Method of measurement: cooperman questionnaire.;Sweating rate. Timepoint: Before and one month after the intervention. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Abdollahi

Karaj University of Medical Sciences

S.abdolahi@abzums.ac.ir+98 26 3222 2021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026